Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

August 16, 2007

Primary Completion Date

March 8, 2017

Study Completion Date

March 8, 2017

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

Methoxyamine

For all cycles, TMZ will be given orally for 5 days every 28 days. MX will be given as a single one-hour IV infusion every 28 days. Temozolomide will be administered within 5 minutes following the initiation of methoxyamine.

DRUG

Temozolomide

Patients receive oral temozolomide once daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Trial Locations (1)

44106

University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Case Comprehensive Cancer Center

OTHER

NCT00892385 - Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter